GlassScriptPhysician profile
Victoria Bates
NPI 1710316062
$14,385.89
in general payments reported to CMS, 2019-2025
27 companies · $4,352 in 2025
The $4,352 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,059 · 2022: $1,514 · 2023: $3,397 · 2024: $4,064 · 2025: $4,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,175.24 |
| Education | $637.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,340.34 | 2021-2025 | |
| Janssen Biotech, INC. | $1,476.24 | 2022-2025 | Tremfya |
| Leo Pharma INC. | $1,026.67 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $1,002.25 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $992.87 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $979.06 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $976.23 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $909.16 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $892.57 | 2021-2025 | Opzelura |
| Genzyme Corporation | $868.38 | 2021-2025 | |
| Lilly USA, LLC | $653.38 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $503.90 | 2021-2025 | |
| Galderma Laboratories, L.P. | $350.16 | 2021-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $335.10 | 2023-2024 | Vtama |
| Organon LLC | $222.96 | 2024-2025 | Hadlima, Vtama, Nexplanon |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $207.99 | 2024-2025 | Zoryve |
| Amgen INC. | $181.96 | 2021-2025 | Otezla, Otezla |
| Strata Skin Sciences, INC. | $107.65 | 2024-2025 | Xtrac |
| Sanofi-Aventis U.S. LLC | $98.77 | 2021 | |
| Biofrontera INC. | $71.87 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Sandoz INC. | $37.93 | 2023 | Hyrimoz |
| Fresenius Kabi USA, LLC | $30.98 | 2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.61 | 2022 | |
| Kyowa Kirin, INC. | $28.63 | 2024 | Poteligeo |
| Krystal Biotech INC | $25.14 | 2024 | Vyjuvek |
| Organogenesis INC. | $18.34 | 2025 | Simplimax |
| Mimedx Group, INC. | $16.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.